Cargando…
PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431417/ http://dx.doi.org/10.1097/01.HS9.0000850908.45753.c0 |
| _version_ | 1784780049415667712 |
|---|---|
| author | Sasaki, M. Suzuki, K. Abe, Y. Ito, S. Nishiwaki, K. Handa, H. Chou, T. Soeda, J. Mori, I. Shinozaki, T. Takezako, N. |
| author_facet | Sasaki, M. Suzuki, K. Abe, Y. Ito, S. Nishiwaki, K. Handa, H. Chou, T. Soeda, J. Mori, I. Shinozaki, T. Takezako, N. |
| author_sort | Sasaki, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431417 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94314172022-08-31 PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Sasaki, M. Suzuki, K. Abe, Y. Ito, S. Nishiwaki, K. Handa, H. Chou, T. Soeda, J. Mori, I. Shinozaki, T. Takezako, N. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431417/ http://dx.doi.org/10.1097/01.HS9.0000850908.45753.c0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Sasaki, M. Suzuki, K. Abe, Y. Ito, S. Nishiwaki, K. Handa, H. Chou, T. Soeda, J. Mori, I. Shinozaki, T. Takezako, N. PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2019: efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable proteasome inhibitor-based therapy in patients with relapsed/refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431417/ http://dx.doi.org/10.1097/01.HS9.0000850908.45753.c0 |
| work_keys_str_mv | AT sasakim pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT suzukik pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT abey pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT itos pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT nishiwakik pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT handah pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT chout pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT soedaj pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT morii pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT shinozakit pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma AT takezakon pb2019efficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectableproteasomeinhibitorbasedtherapyinpatientswithrelapsedrefractorymultiplemyeloma |